The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multidisciplinary collaborative research approach at OSU has a tract record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast cancer, gastrointestinal cancers, genitourinary malignancies, hematologic malignancies, lung cancer and melanoma. This research focuses the efforts of medical and hematologic oncologists, surgeons, radiotherapists, transplanters, psychiatrists, pathologists, cytogeneticists, translational laboratory scientists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk. Included in this project are: 1) the exploration of new therapeutic agents, and their associated toxicities, in Phase I, II and III clinical trials; 2) the evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology and biostatistics in the formulation and execution of specific therapy protocols; 5) the improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) the evaluation of biologic studies in correlation with clinical endpoint to develop more rationally based cancer management, 7) the evaluation of cancer controls efforts such as early detection, and 8) the study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core laboratories and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA077658-11
Application #
7456463
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-04-16
Project End
2009-03-31
Budget Start
2008-04-03
Budget End
2009-03-31
Support Year
11
Fiscal Year
2008
Total Cost
$450,518
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Rizzotto, Lara; Lai, Tzung-Huei; Bottoni, Arianna et al. (2018) Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leuk Lymphoma 59:1461-1465
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Walker, Christopher J; Oakes, Christopher C; Genutis, Luke K et al. (2018) Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia :
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Papaioannou, Dimitrios; Nicolet, Deedra; Volinia, Stefano et al. (2017) Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica 102:1391-1400
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2017) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res 77:207-218
Eisfeld, A-K; Kohlschmidt, J; Schwind, S et al. (2017) Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 31:1278-1285
Walker, C J; Eisfeld, A-K; Genutis, L K et al. (2017) No evidence for microsatellite instability in acute myeloid leukemia. Leukemia 31:1474-1476

Showing the most recent 10 out of 222 publications